Literature DB >> 20619835

Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels.

P Fritsch1, M Kleber, A Rosenkranz, M Fritsch, W Muntean, H Mangge, T Reinehr.   

Abstract

BACKGROUND: The metabolic syndrome (MetS) is associated with central obesity and leads to increased morbidity and mortality due to cardiovascular disease (CVD). Since obesity is associated with a hypercoagulable state, it has been speculated that hypercoagulation is linking MetS to CVD.
METHODS: We prospectively examined 81 overweight children and 32 normal-weight children aged 10-16 years. We analyzed blood pressure, fasting lipids, glucose, insulin, fibrinogen, and thrombin generating test determining time to peak (TTPeak), peak, time preceding the thrombin burst (lag-time), and 'endogenous' thrombin potential (ETP).
RESULTS: Overweight children demonstrated significantly higher fibrinogen levels (p<0.001), shorter lag-time (p<0.001), and TTPeak (p=0.038) compared to normal-weight children. Furthermore, ETP (p<0.001) and peak (p<0.001) were significantly higher in overweight than in normal-weight children. Fibrinogen and all parameters of the clotting test correlated significantly (p always <0.05) to body mass index (BMI) but not significantly to insulin resistance index HOMA-IR or occurrence of MetS in multiple linear backward regression analyses adjusted for age and gender.
CONCLUSIONS: The increased fibrinogen levels and the changes in the thrombin generation test points towards a haemostatic alteration in overweight children. The parameters of the clotting test were related to the degree of overweight but not to insulin resistance or occurrence of MetS questioning a direct association between MetS and the coagulation system. Longitudinal studies are needed to confirm these findings.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619835     DOI: 10.1016/j.atherosclerosis.2010.06.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Impact of obesity on the risk of venous thromboembolism in an inpatient pediatric population.

Authors:  Sean Stokes; Patrick Breheny; Aurelia Radulescu; Vlad Calin Radulescu
Journal:  Pediatr Hematol Oncol       Date:  2014-03-31       Impact factor: 1.969

2.  Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Authors:  Anna K Kopec; Nikita Joshi; Keara L Towery; Karen M Kassel; Bradley P Sullivan; Matthew J Flick; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-08-19       Impact factor: 4.030

3.  Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.

Authors:  Karen M Kassel; A Phillip Owens; Cheryl E Rockwell; Bradley P Sullivan; Ruipeng Wang; Ossama Tawfik; Guodong Li; Grace L Guo; Nigel Mackman; James P Luyendyk
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

4.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

5.  Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?

Authors:  S Koutroumpi; L Spiezia; N Albiger; M Barbot; M Bon; S Maggiolo; S Gavasso; P Simioni; A Frigo; F Mantero; C Scaroni
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

6.  Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium.

Authors:  Jignesh P Patel; Raj K Patel; Lara N Roberts; Michael S Marsh; Bruce Green; J Graham Davies; Roopen Arya
Journal:  BMC Pregnancy Childbirth       Date:  2014-11-19       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.